Rezdiffra (Resmetirom) for NASH F2-F3: Evidence Summary

Rezdiffra Is FDA-Approved for NASH F2-F3 (Not Off-Label)

Resmetirom received accelerated approval from the U.S. Food and Drug Administration on March 14, 2024, for adults with noncirrhotic MASH and moderate to advanced liver fibrosis (stages F2 to F3), confirmed by liver biopsy 1. This makes resmetirom the first pharmacotherapy ever approved specifically for this condition. Prescribing Rezdiffra for biopsy-confirmed NASH with F2 or F3 fibrosis is on-label use.

The distinction matters for patients and clinicians weighing treatment decisions. Because the indication requires biopsy confirmation of fibrosis stage, use in patients staged only by noninvasive tests (such as FibroScan or FIB-4 scores) without biopsy would technically fall outside the labeled indication. The approval came through the accelerated pathway, meaning it was based on surrogate histological endpoints (NASH resolution and fibrosis improvement on biopsy), with a confirmatory outcomes trial, MAESTRO-NASH Outcomes, still underway 2. Full approval depends on whether resmetirom reduces clinical events like progression to cirrhosis, liver transplant, or death.

The nomenclature shift from NASH to MASH reflects the 2023 consensus by a multi-society Delphi panel, but both terms describe the same histological entity 3. Rezdiffra's labeling uses both terms interchangeably.

The MAESTRO-NASH Trial: Core Evidence

The phase 3 MAESTRO-NASH trial enrolled 966 adults with biopsy-confirmed NASH and stage F1B, F2, or F3 fibrosis, randomizing them to resmetirom 80 mg, resmetirom 100 mg, or placebo once daily for 52 weeks 2. Both co-primary endpoints were assessed by central pathology reading of paired liver biopsies at baseline and week 52.

Results at 52 weeks in the F2-F3 subgroup (the population that formed the basis for approval):

NASH resolution without worsening of fibrosis occurred in 25.9% of the 80 mg group and 29.9% of the 100 mg group, compared with 9.7% in the placebo group (P<0.001 for both comparisons) 2.

Fibrosis improvement by at least one stage without worsening of the NAFLD Activity Score (NAS) was observed in 24.2% of patients on 80 mg and 25.9% on 100 mg, versus 14.2% on placebo (P<0.001 for 100 mg; P=0.0002 for 80 mg) 2.

These numbers deserve context. A 29.9% response rate might seem modest, but the placebo-adjusted difference of roughly 20 percentage points for NASH resolution is the largest treatment effect demonstrated in any phase 3 NASH trial to date. Dr. Stephen Harrison, the trial's lead investigator, stated: "For the first time, we have a drug that achieves both NASH resolution and fibrosis improvement in a significant proportion of patients with F2 and F3 fibrosis" 2.

The trial also measured changes in hepatic fat content by MRI-PDFF. At week 52, relative liver fat reduction reached approximately 51% in the 100 mg group versus 10% with placebo 4. This magnitude of fat reduction correlates with histological improvement in prior NASH imaging studies.

How Resmetirom Works: THR-β Selective Agonism

Resmetirom is a selective agonist of thyroid hormone receptor-beta (THR-β), which is the predominant thyroid hormone receptor isoform in hepatocytes 5. By activating THR-β without stimulating THR-α (the isoform responsible for cardiac and bone effects of thyroid hormone), resmetirom increases hepatic fatty acid oxidation and reduces lipogenesis in the liver. It does not cause systemic thyrotoxicosis.

The mechanism has several downstream metabolic effects. Resmetirom lowers LDL cholesterol by upregulating hepatic LDL receptor expression, a pathway similar to thyroid hormone's known lipid-lowering action. In MAESTRO-NASH, the 100 mg dose reduced LDL-C by approximately 14% from baseline, and lowered triglycerides and lipoprotein(a) as well 2. These lipid changes may carry independent cardiovascular benefit in a population already burdened by metabolic syndrome.

THR-β activation also reduces levels of hepatic SHBG and other liver-derived proteins involved in inflammation. Animal models show that resmetirom decreases hepatic collagen deposition, providing a direct antifibrotic signal beyond simple fat clearance 5. Whether these preclinical antifibrotic effects translate into long-term clinical fibrosis regression in humans is a question the MAESTRO-NASH Outcomes trial aims to answer.

Dosing, Titration, and Monitoring Protocol

Rezdiffra's prescribing information specifies a mandatory titration schedule 1. Patients begin at 80 mg orally once daily with food for the first 60 days, then increase to 100 mg once daily. The tablets should be swallowed whole and taken with a meal to optimize absorption. Splitting or crushing is not recommended.

Baseline liver function tests (ALT, AST, total bilirubin, alkaline phosphatase) are required before initiating therapy. The FDA label mandates monitoring hepatic function at months 3, 6, 9, and 12 during the first year, and periodically thereafter. Treatment should be discontinued if a patient develops signs of drug-induced liver injury, specifically ALT or AST elevations exceeding 5 times the upper limit of normal, or elevations accompanied by clinical symptoms or rising bilirubin 6.

Thyroid function monitoring is not routinely required because resmetirom's selectivity for THR-β spares the hypothalamic-pituitary-thyroid axis at approved doses. TSH levels remained stable across treatment groups in MAESTRO-NASH 2. Patients with pre-existing thyroid disease can use resmetirom, but clinicians should be aware of theoretical additive effects in patients already on exogenous levothyroxine.

Safety Profile and Side Effects

The safety database for resmetirom spans over 2,000 patient-years across the MAESTRO clinical program. The most common adverse events in MAESTRO-NASH were gastrointestinal: diarrhea (27% with 100 mg vs. 17% placebo) and nausea (20% with 100 mg vs. 12% placebo) 2. Most GI events were mild to moderate, occurred early in treatment, and resolved without dose modification.

Serious adverse events occurred at similar rates across treatment and placebo groups. Discontinuation due to adverse events was 6.8% with 100 mg resmetirom versus 2.5% with placebo 2. No cases of Hy's law (ALT >3x ULN with bilirubin >2x ULN) were attributed to resmetirom in the trial.

Bone mineral density is a theoretical concern with any thyroid hormone pathway drug. THR-α mediates thyroid hormone's catabolic bone effects, and resmetirom's selectivity for THR-β should bypass this pathway. Bone density data from the MAESTRO program showed no significant decreases over 52 weeks 4. Long-term bone safety surveillance remains important.

Heart rate increases were minimal. Mean resting heart rate rose by approximately 1 to 2 beats per minute in the resmetirom groups, a clinically insignificant change 2. No arrhythmia signal emerged. The American Association of Clinical Endocrinology (AACE) guidelines note that resmetirom's cardiac safety profile is "reassuring given the known cardiac effects of non-selective thyromimetics" 7.

Patient Selection: Who Is a Candidate

The labeled indication limits Rezdiffra to adults with noncirrhotic MASH and F2-F3 fibrosis confirmed by liver biopsy. This means several patient groups fall outside the current approval. Patients with F0-F1 fibrosis are excluded. So are patients with compensated cirrhosis (F4), even though the MAESTRO-NASH Outcomes trial includes some F4 patients 2. Patients diagnosed solely by noninvasive markers (vibration-controlled transient elastography, FIB-4, or ELF score) without a confirmatory biopsy are also not within the labeled indication.

In practice, clinicians face a gap. Liver biopsy carries procedural risk and cost, and many patients with probable F2-F3 fibrosis identified by noninvasive testing may be reluctant to undergo biopsy solely to access a medication. The AASLD Practice Guidance on NAFLD management acknowledges this tension but currently endorses biopsy as the reference standard for treatment eligibility in clinical settings using approved therapies 8.

Patients with concurrent metabolic conditions, including type 2 diabetes and obesity, were well-represented in MAESTRO-NASH. Approximately 67% of enrolled participants had type 2 diabetes, and mean BMI was around 36 kg/m² 2. Resmetirom demonstrated efficacy regardless of diabetes status. Use alongside GLP-1 receptor agonists was permitted in the trial and did not produce safety signals, though dedicated interaction studies are limited.

Liver Fat, Biomarkers, and Noninvasive Endpoints

Beyond the histological endpoints, MAESTRO-NASH collected extensive noninvasive biomarker data that help contextualize treatment response. Resmetirom 100 mg reduced MRI-PDFF liver fat fraction by a relative 51% at 52 weeks compared with approximately 10% in the placebo group 4. Absolute liver fat reduction exceeded 8 percentage points in many patients, crossing the clinically meaningful threshold of >30% relative reduction associated with histological improvement in prior validation studies 9.

ALT levels, a surrogate for hepatic inflammation, declined by about 25% from baseline in the 100 mg group. Reductions in GGT and other liver enzymes followed a similar pattern. These changes were apparent by week 12 and sustained through week 52 2.

Lipid changes provided an unexpected secondary benefit. LDL-C dropped approximately 14%, apolipoprotein B fell by 10%, and lipoprotein(a) decreased by roughly 25% with the 100 mg dose 2. Dr. Arun Sanyal, a hepatologist at Virginia Commonwealth University and co-investigator on MAESTRO-NASH, noted: "The combined hepatic and cardiometabolic effects of resmetirom position it uniquely among NASH therapeutics, because it addresses liver disease and cardiovascular risk simultaneously" 10.

These lipid effects are not trivial. Cardiovascular disease, not liver failure, is the leading cause of death in NASH patients 11. A drug that reduces liver fat, improves histology, and lowers atherogenic lipoproteins addresses multiple mortality drivers within a single mechanism.

Cost, Access, and Insurance Considerations

Rezdiffra's wholesale acquisition cost (WAC) is approximately $47,400 per year 1. As the first drug in its class and the only FDA-approved NASH therapy, it has no generic equivalent or therapeutic alternative with the same labeled indication. Madrigal Pharmaceuticals, the manufacturer, operates a patient assistance program (Rezdiffra Connect) for commercially insured and uninsured patients.

Insurance coverage remains uneven. Many commercial payers require prior authorization with documentation of biopsy-confirmed F2 or F3 fibrosis, a documented trial of lifestyle modification, and evidence of ongoing metabolic comorbidities. Some payers have added step therapy requirements including GLP-1 agonists or pioglitazone before approving Rezdiffra, though neither of those drugs carries an FDA indication for NASH 12.

Medicare Part D coverage varies by plan formulary. The accelerated approval status has led certain plans to restrict coverage pending the confirmatory outcomes data, a pattern seen with other conditionally approved drugs. Patients experiencing coverage denials should work with their hepatologist's office to submit a peer-to-peer review or formal appeal with biopsy documentation.

Where the Evidence Stands: Ongoing Trials and Gaps

The accelerated approval carries a post-marketing commitment. The MAESTRO-NASH Outcomes trial (NCT05500222) is a large, event-driven study enrolling approximately 2,000 patients with MASH and F2-F4 fibrosis, with a primary endpoint of time to first occurrence of a composite liver outcome (progression to cirrhosis, liver decompensation, transplant, or liver-related death) 2. Results are expected around 2028. If the trial fails to demonstrate clinical benefit, the FDA can withdraw the accelerated approval.

Open questions remain. Treatment duration is undefined. The optimal strategy for patients who achieve histological response (continue indefinitely versus taper or stop) has not been studied. Whether noninvasive tests can reliably substitute for biopsy in identifying treatment responders is under active investigation. The role of combination therapy (resmetirom plus a GLP-1 agonist, for example) is being explored in early-phase protocols but lacks phase 3 data.

For now, resmetirom represents a validated, evidence-based treatment for biopsy-confirmed MASH with F2-F3 fibrosis, backed by a well-powered phase 3 trial and an FDA approval. Clinicians prescribing it within this labeled indication should monitor hepatic function per the label schedule, titrate from 80 mg to 100 mg at day 60, and counsel patients that GI side effects typically diminish within the first few weeks of treatment 6.